For the quarter ending 2026-03-31, TRAW had -$687K decrease in cash & cash equivalents over the period.
| Cash Flow | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| Net (loss) income | -7,107 | -7,443 | -3,962 | 20,575 |
| Change in fair value of warrant liability | 159 | 89 | 3 | -26,659 |
| Depreciation and amortization | 44 | 44 | 15 | 2 |
| Stock-based compensation | 634 | 327 | 135 | 266 |
| Receivables | -2,107 | 1,803 | 668 | -442 |
| Prepaid expenses and other current assets | 480 | -849 | 248 | -882 |
| Deferred revenue | - | -1 | 1 | -2,791 |
| Other assets | -5 | - | - | - |
| Accounts payable | 2,012 | 2,469 | 524 | -3,605 |
| Accrued expenses and other current liabilities | 50 | 2,711 | 189 | -528 |
| Net cash used in operating activities | -2,576 | -2,758 | -4,011 | -11,416 |
| Payment of offering costs | - | 1,939 | 178 | 287 |
| Cash paid for acquisition, net of cash acquired | - | 0 | 2,585 | - |
| Proceeds from exercised prefunded warrants | - | 10 | 0 | 16 |
| Net cash used in investing activities | - | 0 | -2,585 | - |
| Proceeds from sale of common stock pursuant to the atm | 1,897 | 2,087 | 116 | 3,379 |
| Net cash provided by financing activities | 1,897 | 158 | -62 | 3,108 |
| Effect of foreign currency translation on cash | -8 | 0 | -3 | 51 |
| Net (decrease) increase in cash and cash equivalents | -687 | -2,600 | -6,661 | -8,257 |
| Cash and cash equivalents at beginning of period | 3,820 | 6,420 | 21,338 | - |
| Cash and cash equivalents at end of period | 3,133 | 3,820 | 6,420 | - |
Traws Pharma, Inc. (TRAW)
Traws Pharma, Inc. (TRAW)